Drugs / PARIGLASGENE BRECAPARVOVEC
PARIGLASGENE BRECAPARVOVEC
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03517085 | May 2018 → Nov 2021 | glycogen storage disease I | Ultragenyx Pharmaceutical Inc | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT05139316 | Nov 2021 → Feb 2024 | glycogen storage disease due to glucose-6-phosphatase deficiency type IA | Ultragenyx Pharmaceutical Inc | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PARIGLASGENE BRECAPARVOVEC | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095444 ↗ |
| Known as | AAV8G6PASE | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095444 ↗ |
| Known as | AAV8G6PC | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095444 ↗ |
| Known as | DTX401 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05139316 ↗ |
| Route | Intravenous | “DTX401 administered as a single peripheral intravenous (IV) infusion” NCT03517085 ↗ |